[
    "<p>",
    "This paper shows details of the protocol ",
    "Design for the Brazilian Registry of Patients with Immuno-mediated Chronic Inflammatory Diseases Infected by Sars-Cov-2 (ReumaCoV-Brasil) (Brazilian Register of Clinical Trials \u2013 RBR-33YTQC, registered on June, 1<sup>st, </sup>2020).</p><p><br></p><p>1.",
    "Data collection began in May 2020, using a convenience sampling strategy.</p><p>2.",
    "The data will be collected at three distinct periods: inclusion, 3 months, and 6 months.",
    "Participating centers were selected based on their expressed interest after a collective invitation had been sent to all rheumatologists affiliated to the Brazilian Society of Rheumatology.",
    "Most of them are public reference centers involved in teaching and forming fellows in rheumatology, but some have focus in private care.&nbsp;</p><p>3.",
    "Regardless COVID-19 diagnosis, the eligible patients ",
    "Include those aged 18 years or over with prior diagnosis of IMRD, according to the American College of Rheumatology (ACR) or European League against Rheumatism (EULAR) criteria, including rheumatoid arthritis (RA)[14, 15], systemic lupus erythematosus (SLE)[16, 17], Sj\u00f6gren's syndrome (SS)[18], systemic sclerosis (ES)[19], inflammatory myopathies[20], axial spondyloarthritis[21-23], enteropathic arthritis[24], psoriatic arthritis[25]&nbsp;sarcoidosis[26], antiphospholipid syndrome (APS)[27],",
    "Beh\u00e7et disease [28], mixed connective tissue disease[29], Takayasu arteritis[30, 31], giant cell arteritis[32], ANCA-associated vasculitides[33-36] and juvenile idiopathic arthritis at adult age [37].</p><p>4.",
    "The exclusion criteria were other immunodeficiency diseases, past organ or bone marrow transplantation, neoplasms within the last five years, current chemotherapy, HIV diagnosis and thymus diseases.",
    "The controls (not exposed) will be patients with IMRD without suggestive symptoms or diagnosis of COVID-19, matched for sex, age and IMRD, respecting the same exclusion criteria.</p><p>5.",
    "Cases (exposed) and controls (non exposed)  will be enrolled after reading and signing the informed consent (ICF \u2013 Appendix A).",
    "<",
    "/p><p>6.",
    "The clinical form (Appendix B) will be filled at baseline and 3- and 6-month follow-up using the REDCAp platform.",
    "<",
    "/p><p>7.",
    "A total of 14 mL of blood will be collected for further lab exams, according to the protocol described at figure 3.",
    "</p><p>8.",
    "The blood will be centrifuged at 3000 rpm with serum being separated and stored at -20\u00baC in each participating center and it will be sent to the Hermes Pardini Laboratory posteriorly in a one-way shipping.</p><p>9.",
    "The anti-SARS-CoV-2 antibodies (IgM and IgG) will be evaluated by ELISA (Euroimmun\u00ae), using plasma aliquots, according to the manufacturer\u2019s recommendations.",
    "Rheumatoid factor, anti-CCP, ANA, anticardiolipin (IgG and IgM) and immunoglobulins (IgM, IgG and IgA) will be tested using serum aliquots, using pre-established protocols.</p><p>10.",
    "The total blood and another one tube that the RNAlater was added will be shipped to the LIKA (Keizo Asami Immunopathology Laboratory), located at Federal University of Pernambuco (UFPE) and maintained at -80oC until the genetic and epigenetics evaluation.</p><p>11.",
    "The primary outcomes will be the IMRD disease activity changes after COVID-19, at four time points: (1) At baseline or recording data in the last 6 months; (2) The first rheumatic evaluation after COVID-19 (4-6 weeks); (3) 3 months after the inclusion (\u00b115 days); (4) 6 months after inclusion (\u00b115 days) (Table 2).",
    "</p><p>12.",
    "Details about previous lab exams will also be recorded, such as ESR, CRP, rheumatoid factor, anti-CCP, ANA, anti-ENA, anti-double-stranded-DNA, HLA-B27, complement, anticardiolipin IgG and IgM, ANCA and cryoglobulins.</p><p><br></p><p><br></p>"
]